Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.350
-0.010 (-0.42%)
At close: Dec 31, 2025, 4:00 PM EST
2.333
-0.017 (-0.71%)
After-hours: Dec 31, 2025, 7:53 PM EST
Palisade Bio Stock Forecast
Stock Price Forecast
The 3 analysts that cover Palisade Bio stock have a consensus rating of "Strong Buy" and an average price target of $17.67, which forecasts a 651.91% increase in the stock price over the next year. The lowest target is $12 and the highest is $25.
Price Target: $17.67 (+651.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palisade Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Clear Street | Clear Street | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +410.64% | Dec 30, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $25 | Buy | Initiates | $25 | +963.83% | Dec 29, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +580.85% | May 13, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +1,517.02% | Nov 20, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $23 → $8 | Strong Buy | Maintains | $23 → $8 | +240.43% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.19
from -10.19
EPS Next Year
-0.58
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.19 | -0.17 | ||||
| Avg | -1.19 | -0.58 | ||||
| Low | -1.80 | -1.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.